THERAVANCE INC Form 10-Q/A August 15, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2007

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 0-30319

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

94-3265960

(State or Other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)

901 Gateway Boulevard South San Francisco, CA 94080

(Address of Principal Executive Offices including Zip Code)

(650) 808-6000

(Registrant s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one)

Large Accelerated Filer x Accelerated Filer o Non-Accelerated Filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

The number of shares of registrant s common stock outstanding on July 31, 2007 was 51,259,839.

The number of shares of registrant s Class A common stock outstanding on July 31, 2007 was 9,401,498.

This Amendment No. 1 on Form 10-Q/A (this Amendment) amends the Quarterly Report on Form 10-Q for the quarter ended June 30,2007 of Theravance, Inc. (the Company) filed with the Securities and Exchange Commission on August 8,2007 (the Original Form 10-Q). This Amendment is being filed solely to correct an error on the cover page of the Original Form 10-Q. The Original Form 10-Q incorrectly reported that there were 60,661,337 shares of the Company s common stock outstanding at July 31,2007. The cover page of this Amendment reports the correct number of shares of the Company s common stock that were outstanding at July 31,2007, or 51,259,839 shares.

This Amendment does not modify or update the disclosure in the Original Form 10-Q other than as described in the previous paragraph.

2

Item 6. Exhibits

Exhibit Number 31.1 Exhibit Description 31.2 Exhibit Description Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended

3

SIGNATURES

Pursuant to the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Theravance, Inc. (Registrant)

August 15, 2007

Date

/s/ Rick E Winningham Rick E Winningham Chief Executive Officer

August 15, 2007

Date

/s/ Michael W. Aguiar Michael W. Aguiar Senior Vice President, Finance and Chief Financial Officer

4

EXHIBIT INDEX

Exhibit	
Number 31.1	Exhibit Description Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended
31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended
5	